European Journal of Molecular & Clinical Medicine

Abstract

Introduction: mucormycosis (ROCM) is a aggressive infection and in patient with co-morbidities, the mortality rises upto 50%. Rhino-orbitocerebral mucormycosis (ROCM) is the more common in patients with poor diabetic control and usually manifests itself as nasal stuffiness, nasal discharge, facial pain. Eye signs involve opthalmoplagia, proptosis and in advanced stages loss of vision.
Material & Methods:
This is a prospective, cross-sectional study involving patients who reported to our centre and those patients who were referred from other hospital for treatment of mucormycosis during the second of COVID-19 during april – june 2021.
Results:Majority of the patients were above 50 years of age and the most common co-morbidity was diabetes. Maxilla was more commonly involved than mandible. Posaconazole along with surgical debridement effectively controlled the disease process. All the patients were disease free at 6 months follow up
Discussion: Combined team work, creating a task force team for mucormycosis, effective anti-fungal therapy along with surgical debridement played a key role in management of mucormycosis with no recurrence. Control of co-morbidities remained as part of the patient care and has helped in control of the disease process and prevention of secondary infections